LT5024B - Gliburido kompozicija - Google Patents

Gliburido kompozicija Download PDF

Info

Publication number
LT5024B
LT5024B LT2002085A LT2002085A LT5024B LT 5024 B LT5024 B LT 5024B LT 2002085 A LT2002085 A LT 2002085A LT 2002085 A LT2002085 A LT 2002085A LT 5024 B LT5024 B LT 5024B
Authority
LT
Lithuania
Prior art keywords
glyburide
microns
drug
tablet
fine particles
Prior art date
Application number
LT2002085A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2002085A (en
Inventor
Gillian Cave
Sarah J. Nicholson
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT2002085A publication Critical patent/LT2002085A/xx
Publication of LT5024B publication Critical patent/LT5024B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
LT2002085A 2000-01-14 2002-07-23 Gliburido kompozicija LT5024B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48370300A 2000-01-14 2000-01-14

Publications (2)

Publication Number Publication Date
LT2002085A LT2002085A (en) 2003-01-27
LT5024B true LT5024B (lt) 2003-06-25

Family

ID=23921174

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002085A LT5024B (lt) 2000-01-14 2002-07-23 Gliburido kompozicija

Country Status (37)

Country Link
US (2) US20010036479A1 (es)
EP (1) EP1250321B1 (es)
JP (1) JP4787446B2 (es)
KR (1) KR100739906B1 (es)
CN (1) CN1210258C (es)
AR (1) AR031547A1 (es)
AT (1) ATE330937T1 (es)
AU (1) AU771705B2 (es)
BG (1) BG65782B1 (es)
BR (1) BR0107564A (es)
CA (1) CA2397294C (es)
CY (1) CY1106328T1 (es)
CZ (1) CZ20022429A3 (es)
DE (1) DE60120916T2 (es)
DK (1) DK1250321T3 (es)
EE (1) EE05020B1 (es)
ES (1) ES2264967T3 (es)
GE (1) GEP20043299B (es)
HU (1) HU228825B1 (es)
IL (2) IL150383A0 (es)
LT (1) LT5024B (es)
LV (1) LV12914B (es)
MX (1) MXPA02006835A (es)
MY (1) MY128577A (es)
NO (1) NO328152B1 (es)
NZ (1) NZ519920A (es)
PT (1) PT1250321E (es)
RO (1) RO121381B1 (es)
RU (1) RU2244707C2 (es)
SK (1) SK286925B6 (es)
TN (1) TNSN01005A1 (es)
TR (1) TR200201798T2 (es)
TW (1) TWI287989B (es)
UA (1) UA73968C2 (es)
UY (1) UY26529A1 (es)
WO (1) WO2001051463A1 (es)
ZA (1) ZA200205528B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
JP2005527537A (ja) * 2002-03-21 2005-09-15 テバ ファーマシューティカル インダストリーズ リミティド 微小粒度ピオグリタゾン
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
WO2005041962A1 (en) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
CN100455279C (zh) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 口服延迟释放锭剂组成物及其制法
JP2007534704A (ja) * 2004-04-29 2007-11-29 美時化学製薬股▲ふん▼有限公司 経口徐放性錠剤組成物およびその製造方法
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
WO2006109175A2 (en) * 2005-04-11 2006-10-19 Aurobindo Pharma Limited Solid dosage form of an antidiabetic drug
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
US7776870B2 (en) 2005-08-22 2010-08-17 Melior Pharmaceuticals I, Inc. Methods for modulating Lyn kinase activity and treating related disorders
CN101287467B (zh) * 2005-08-22 2011-01-19 梅里奥尔医药I公司 用于调节Lyn激酶活性和治疗相关病症的方法和制剂
JP2009537478A (ja) * 2006-05-13 2009-10-29 ノヴォ ノルディスク アクティーゼルスカブ レパグリニドとメトホルミンを含む錠剤配合物
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US8883852B2 (en) 2008-10-22 2014-11-11 University of Pittburgh—Of the Commonwealth System of Higher Education Radioprotective agents
EP2520298A1 (en) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
CN102743354A (zh) * 2012-07-31 2012-10-24 南京正科制药有限公司 瑞格列奈片及其制备方法
CN103142521B (zh) * 2013-03-21 2014-06-25 西南药业股份有限公司 格列本脲片及其制备方法
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
CN104127423A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列喹酮衍生物及其制备方法和应用
EP3609500A4 (en) 2017-04-10 2020-08-19 Melior Pharmaceuticals I, Inc. ADIPOCYTE TREATMENT
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
WO2023012610A1 (en) * 2021-08-03 2023-02-09 Avaca Pharma Private Limited Formulations, compositions and methods for the treatment of stroke

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426067A (en) 1963-10-19 1969-02-04 Hoechst Ag Benzenesulfonyl ureas and process for their manufacture
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US3979520A (en) 1973-09-26 1976-09-07 Boehringer Mannheim G.M.B.H. Preparation of rapidly resorbable glibenclamide
US4060634A (en) 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
US5258185A (en) 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
CA889876A (en) 1970-09-10 1972-01-04 Frank W. Horner Limited Purification of glyburide
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
RU2026670C1 (ru) 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
AU671965B2 (en) * 1991-12-05 1996-09-19 Alfatec-Pharma Gmbh Pharmaceutically Applicable Nanosol and Process for Preparing The Same
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19721467A1 (de) * 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
PT996444E (pt) 1997-06-18 2007-06-08 Smithkline Beecham Plc Tratamento de diabetes com tiazolidinodiona e metformina
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
ES2191977T3 (es) * 1997-10-27 2003-09-16 Merck Patent Gmbh Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.
DK0974356T3 (da) 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426067A (en) 1963-10-19 1969-02-04 Hoechst Ag Benzenesulfonyl ureas and process for their manufacture
US3507961A (en) 1963-10-19 1970-04-21 Hoechst Ag Benzenesulfonyl ureas as anti-diabetic agents
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US3507954A (en) 1965-07-27 1970-04-21 Hoechst Ag Benzenesulfonyl-ureas as anti-diabetic agents
US3979520A (en) 1973-09-26 1976-09-07 Boehringer Mannheim G.M.B.H. Preparation of rapidly resorbable glibenclamide
US4060634A (en) 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
US5258185A (en) 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARNQVIST HJ, KARLBERG BE, MELANDER A: "Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes.", ANN CLIN RES, 1983, pages 21 - 25, XP000993012
J. A. GANLEY ET AL.: "The effect of in-vivo dispersion and gastric emptying on glibenclamide absorption from a novel, rapidly dissolving capsule formulation", JOURNAL OF PHARMACY AND PHARMACOLOGY, 1984, pages 734 - 739
OMAR SHAHEEN ET AL.: "Comparison of pharmacokinetics and pharmacodynamics of a conventional and a new rapidly dissolving glibenclamide preparation", INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1987, pages 123 - 131

Also Published As

Publication number Publication date
HUP0203852A2 (hu) 2003-04-28
KR100739906B1 (ko) 2007-07-16
IL150383A (en) 2007-03-08
IL150383A0 (en) 2002-12-01
DE60120916D1 (de) 2006-08-03
EE05020B1 (et) 2008-06-16
CZ20022429A3 (cs) 2003-06-18
ATE330937T1 (de) 2006-07-15
NO20023367L (no) 2002-09-04
PT1250321E (pt) 2006-09-29
SK9832002A3 (en) 2003-07-01
TNSN01005A1 (en) 2005-11-10
CN1210258C (zh) 2005-07-13
LT2002085A (en) 2003-01-27
US6830760B2 (en) 2004-12-14
CY1106328T1 (el) 2011-10-12
US20010036479A1 (en) 2001-11-01
AU2474001A (en) 2001-07-24
JP2003519681A (ja) 2003-06-24
EP1250321A1 (en) 2002-10-23
AR031547A1 (es) 2003-09-24
MY128577A (en) 2007-02-28
TWI287989B (en) 2007-10-11
HU228825B1 (en) 2013-05-28
LV12914B (en) 2003-01-20
AU771705B2 (en) 2004-04-01
US20030185880A1 (en) 2003-10-02
BR0107564A (pt) 2002-10-01
WO2001051463A1 (en) 2001-07-19
CA2397294A1 (en) 2001-07-19
BG65782B1 (bg) 2009-11-30
CA2397294C (en) 2011-03-22
NZ519920A (en) 2004-06-25
RU2244707C2 (ru) 2005-01-20
ES2264967T3 (es) 2007-02-01
GEP20043299B (en) 2004-03-10
RO121381B1 (ro) 2007-04-30
JP4787446B2 (ja) 2011-10-05
DE60120916T2 (de) 2007-02-15
MXPA02006835A (es) 2003-01-28
UY26529A1 (es) 2001-08-27
DK1250321T3 (da) 2006-07-31
BG106870A (en) 2003-03-31
CN1395560A (zh) 2003-02-05
EE200200393A (et) 2003-10-15
RU2002121626A (ru) 2004-01-10
EP1250321B1 (en) 2006-06-21
NO328152B1 (no) 2009-12-21
HUP0203852A3 (en) 2005-05-30
ZA200205528B (en) 2003-10-10
UA73968C2 (en) 2005-10-17
KR20020073169A (ko) 2002-09-19
PL356210A1 (en) 2004-06-14
TR200201798T2 (tr) 2002-11-21
SK286925B6 (sk) 2009-07-06
NO20023367D0 (no) 2002-07-12

Similar Documents

Publication Publication Date Title
LT5024B (lt) Gliburido kompozicija
US7732492B2 (en) Nateglinide-containing preparation
US20140066482A1 (en) Pharmaceutical Formulation Comprising Metformin and Repaglinide
US20080050443A1 (en) Fast Release Composition Including Melt Granules of a Moisture Sensitive Drug and Process for Manufacturing Thereof
EP0282020B1 (en) Pharmaceutical preparations containing non-steroidal anti-inflammatory agents
WO2006109175A2 (en) Solid dosage form of an antidiabetic drug
US20070219250A1 (en) Pharmaceutical Compositions of Nateglinide
ES2218702T3 (es) Composiciones que contienen un compuesto soluble en agua y celulosa.
WO2005092319A1 (en) Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
WO2022119541A1 (en) A film coated tablet formulation comprising dapagliflozin and metformin hydrochloride
TR202012601A2 (tr) Si̇tagli̇pti̇n ve metformi̇n i̇çeren tablet formülasyonu
PL203547B1 (pl) Kompozycje gliburidu
BRPI0621867A2 (pt) formulação estável que consiste na combinação de uma droga sensìvel à umidade e uma segunda droga, e processo para a sua fabricação

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20210104